Advertisement
Skip to Content

T. Rowe Price Health Sciences I THISX

Analyst rating as of | See T. Rowe Price Investment Hub
  • NAV / 1-Day Return 87.87  /  1.08 %
  • Total Assets 15.4 Bil
  • Adj. Expense Ratio
    0.670%
  • Expense Ratio 0.650%
  • Distribution Fee Level Low
  • Share Class Type Institutional
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 500,000
  • Status Open
  • TTM Yield 0.00
  • Turnover 29%

Morningstar’s Analysis THISX

Will THISX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A good bet in the healthcare sector.

Senior Analyst

Summary

|

T. Rowe Price Health Sciences earns a Morningstar Analyst Rating of Silver because of its capable, well-resourced team and strong investment process parameters.

Unlock our full analysis with Morningstar Investor

Portfolio Holdings THISX

  • Current Portfolio Date Dec 31, 2022
  • Equity Holdings 167
  • Bond Holdings 0
  • Other Holdings 5
  • % Assets in Top 10 Holdings 47.1
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Aggregate Miscellaneous Equity

8.96
1,448,609,013
8.67
1,402,023,897
Healthcare
5.12
827,735,531
Healthcare
4.48
724,986,591
Healthcare
3.80
614,763,150
Healthcare
3.51
566,946,512
Healthcare
3.35
542,347,591
Healthcare
3.16
510,422,078
Healthcare
3.04
491,743,775
Healthcare
2.97
480,096,959
Healthcare